Journal of Theoretical BiologySystems BiologyPeer-reviewed journal article
Rankings of tuberculosis antibiotic treatment regimens are sensitive to spatial scale, detection limit, and initial host bacterial burden
Christian T. MichaeliD, Maral BudakiD, Pauline A MaielloiD, Kara B. Kracinovsky, Mark RodgersiD, Jaime A. TomkoiD, Philana Ling LiniD, JoAnne L. FlynniD, Jennifer J. LindermaniD, Denise E. KirschneriD
Abstract
Pulmonary infection after inhalation of Mycobacterium tuberculosis (Mtb) causes tuberculosis (TB). TB presents with lung granulomas - complex spheroidal structures composed of immune cells and bacteria. Granulomas often have centralized caseum (necrotic tissue) where mycobacteria are quarantined, complicating and prolonging multi-antibiotic regimens. Determining which antibiotic regimens are optimal for reducing treatment time and toxicity is a goal of recent TB eradication campaigns. Clinical trials are expensive and challenging, making it difficult to untangle which host-pathogen interactions drive the heterogeneous infection and treatment outcomes observed at between-host and within-host scales. To determine responses to antibiotic regimens, we simulate treatments in HostSim, our whole-host mechanistic, multi-scale computational model of Mtb-infection. HostSim tracks dynamics of pulmonary Mtb-infection over molecular, cellular, tissue, organ, and whole-host scales. We create a heterogenous virtual cohort, comprising distinct hosts, for virtual clinical trials. We represent drug treatments by newly-integrating pharmacokinetics / pharmacodynamics into HostSim, simulating treatment with commonly-prescribed TB antibiotic regimens (e.g., HRZE or BPaL). Our approach allows us to identify both (1) which hosts/granulomas most improve with treatment, and (2) which mechanisms influence outcome heterogeneity. By tracking experimental and clinical measurements, we virtually recreate several drug rankings from literature. We find that many methods of ranking treatment efficacy are strongly influenced by the definition of improvement used and, in some cases, the detection threshold of CFU. Other rankings depend on initial bacterial burden of hosts/granulomas. Our work suggests that metrics for regimen optimality may be orthogonal, which could explain seemingly-contradictory findings from prior studies.
- Citations
- 4
- FWCI
- 3.06
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Optimizing tuberculosis treatment efficacy: comparing the standard regimen with Moxifloxacin-containing regimens
M. Budak, J. M. Cicchese, … D. E. Kirschner·bioRxiv·Dec 18, 2022
- A virtual host model of Mycobacterium tuberculosis infection identifies early immune events as predictive of infection outcomes
Louis R. Joslyn, Jennifer J. Linderman, Denise E. Kirschner·Journal of Theoretical BiologyPeer-reviewed·Jan 31, 2022
- Multiscale modelling of drug-host-pathogen interaction: quantifying drug and immune contributions to treatment response
Alessandro Ravoni, Enrico Mastrostefano, … Oscar E. Della Pasqua·bioRxiv·Sep 1, 2026
- In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models
Alexa Petrucciani, Alexis Hoerter, … Elsje Pienaar·bioRxiv·Mar 13, 2023
- Cure-screening predicts mechanism of post-antibiotic relapse in Tuberculosis
Christian T. Michael, Maral Budak, … Denise E. Kirschner·bioRxiv·Apr 27, 2026
- Identification and characterization of host-directed therapeutics for tuberculosis using a versatile human 3D tuberculoma bioplatform
Suraj B. Sable, Wen Li, … James E. Posey·bioRxiv·Aug 27, 2025